Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study.

AIMS Previous studies for approved indications (on-label) have shown the good safety and efficacy profiles of the Nobori DES. We conducted a prospective, multicentre study to validate the clinical performance of this stent in a real-world setting. METHODS AND RESULTS A total of 3,067 consecutive patients undergoing a percutaneous coronary intervention with the Nobori DES were enrolled in the NOBORI 2 registry. At one and two years, 97% and 95% of patients, respectively, were available for follow-up. The rates of target lesion failure (TLF), cardiac death, myocardial infarction and target lesion revascularisations were: 3.9%, 1.2%, 1.9% and 2.2% at one year and 5.1%, 1.6%, 2.4% and 3.0% at two years. Overall, 2,242 patients (73%) were treated for at least one off-label indication. When comparing off-label and on-label groups, the results were: TLF 4.5% vs. 2.2%, p=0.003 at one year and 5.9% vs. 2.8%, p=0.001 at two years. The rate of stent thrombosis was 0.68%, and 0.80% at one and two years, respectively with no difference between the off-label and on-label groups (0.76% vs. 0.48%, p=0.6 and 0.89% vs. 0.61%, p=0.5). CONCLUSIONS The promising results previously observed in lower risk patients can be replicated in daily practice. As expected, in off-label indications, rates of adverse events were higher. Nevertheless, our results suggest the good and sustained performance of this stent system in high-risk patients with significant comorbidities and/or complex lesions.

[1]  Yuji Ikari,et al.  Randomized comparison of the nobori biolimus A9‐eluting stent with the sirolimus‐eluting stent in patients with stenosis in native coronary arteries , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  F. Eberli,et al.  Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.

[3]  Mitchell W Krucoff,et al.  A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). , 2011, JACC. Cardiovascular interventions.

[4]  W. Wijns,et al.  Nobori™ drug eluting stent system: clinical evidence update. , 2010, Minerva cardioangiologica.

[5]  Volker Klauss,et al.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.

[6]  P. Block,et al.  Outcomes of unselected recipients of sirolimus-eluting stents: the Cypher stent U.S. post-marketing surveillance registry. , 2010, The Journal of invasive cardiology.

[7]  A. Colombo,et al.  Clinical outcomes after unrestricted implantation of everolimus-eluting stents. , 2009, JACC: Cardiovascular Interventions.

[8]  M. Pencina,et al.  In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. , 2009, JACC. Cardiovascular interventions.

[9]  P. Serruys,et al.  Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial—Phase 2 , 2009, Circulation. Cardiovascular interventions.

[10]  F. Eberli,et al.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.

[11]  Peter L Duffy,et al.  Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. , 2008, JACC. Cardiovascular interventions.

[12]  W. Wijns,et al.  Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. , 2008, Journal of the American College of Cardiology.

[13]  W. Little,et al.  Clinical ResearchInterventional Cardiology“Off-Label” Stent Therapy: 2-Year Comparison of Drug-Eluting Versus Bare-Metal Stents , 2008 .

[14]  H. Bøtker,et al.  Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. , 2008, JAMA.

[15]  R. Wilensky,et al.  A comparison of bare-metal and drug-eluting stents for off-label indications. , 2008, The New England journal of medicine.

[16]  J. Granada,et al.  Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.

[17]  David O. Williams,et al.  Outcomes and complications associated with off-label and untested use of drug-eluting stents. , 2007, JAMA.

[18]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[19]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[20]  P. Serruys,et al.  A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[21]  P. Fitzgerald,et al.  Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial , 2006, Circulation.

[22]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[23]  P. Serruys,et al.  Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. , 2006, Journal of the American College of Cardiology.

[24]  K. Kent,et al.  Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents , 2006, Circulation.

[25]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[26]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[27]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[28]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[29]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[30]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.